

## **ACH4 19th Scientific Conference**

## **ORGANISING COMMITTEE**




Dr Arunasingam (Arun) Abayasingam completed his Bachelor's Degree in Science with Honours at the University of New South Wales in 2016. During his studies, he focused on pathology and pharmacology, undertaking a project investigate the effects of epidermal growth factor receptor targeted and metabolic inhibitor combination therapy in osteosarcomas. In 2017, Arun joined the Viral Immunology Systems Program as a Postgraduate Student under the supervision of Dr Rowena Bull and Dr Chaturaka Rodrigo. His current project includes characterising Hepatitis C (HCV) Transmitted/Founder virus,

understanding the host-viral interaction during acute HCV infection, and investigating the host-viral interactions in HCV re-infection. Findings of this project will potentially contribute towards designing an effective protective vaccine against HCV.



Dr Lindi Masson is Deputy Director of the Women's, Children's and Adolescents' Health Program and Head of the HIV, Inflammation and Microbiome Group at Burnet. The focus of her research is to understand risk factors for sexually transmitted infections, including HIV, and adverse birth outcomes in women and girls. Her work aims to use this knowledge to develop affordable and feasible tools to improve sexual and reproductive health, particularly in resource-limited settings.



Dr Gabriel Duette is a Research Scientist at The Westmead Institute for Medical Research (WIMR) and Adjunct Lecturer at the University of Sydney. He holds the Mathilde Krim Fellowships in Biomedical Research from amfAR (the Foundation for AIDS research). Gabriel co-leads the HIV reservoir group at Centre for Virus Research (CVR), WIMR along with Professor Sarah Palmer. Currently Gabriel is investigating the role of CD8 T cells and HIV persistence in individuals who can control the infection after treatment interruption,

and also in people living with HIV and TB.



A/Prof Grubor-Bauk is the Head of Viral Immunology Group at the Adelaide Medical School, University of Adelaide. She trained as a virologist, immunologist, and vaccine scientist and after postdoctoral training and a period in Biotech, she now leads a collaborative research program which encompasses discovery and translational science components.

Multidisciplinary approach of her group covers areas of translational immunology and vaccine development. We collaborate and work closely with clinician scientists in the areas

of long COVID, severe respiratory illnesses and sepsis, as well as responses to vaccination in immunocompromised and elderly. The group is focussed on the development of novel nucleic acid vaccines (mRNA/pDNA) against different pathogens, for human and veterinary use. Recently we have expanded our research portfolio into development of novel mRNA vaccines in cancer therapy and bacterial infections.